ArticleFrontiers in endocrinology2026
Association of high sensitivity C-reactive protein-triglyceride glucose index and chronic kidney disease: a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) represents a significant global health burden. Its pathogenesis is closely linked to a state of metabolic inflammation, involving insulin resistance and chronic low-grade inflammation. The high-sensitivity C-reactive protein-triglyceride glucose index (CTI) is a novel composite biomarker integrating inflammatory and metabolic information, yet its association with CKD in the general population remains unclear. Objective: This study aimed to investigate the cross-sectional association between the CTI and the prevalence of CKD in a health examination population. Methods: A total of 10-287 adults who underwent routine health check-ups were included. The CTI was calculated as the product of high-sensitivity C-reactive protein (hs-CRP) and the triglyceride-glucose (TyG) index. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m². Logistic regression models were used to assess the association of CTI (as a continuous variable and in quartiles) with CKD. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). The shape of the association and its heterogeneity were explored using restricted cubic splines and subgroup analyses. Results: A total of 163 (1.58%) participants were identified as CKD. After full adjustment for confounders, each unit increase in CTI was associated with a 2.25-fold increased odds of CKD (OR = 2.25, 95%CI: 1.66-3.06). Compared to participants in the lowest CTI quartile, those in the highest quartile had a 2.17-fold higher risk of CKD (OR = 2.17, 95% CI: 1.25-3.76; Conclusion: In a health examination population, a higher CTI level was independently and nonlinearly associated with an increased prevalence of CKD, and it showed better diagnostic performance than individual inflammatory or metabolic markers alone. The CTI may serve as a useful tool for identifying individuals at high risk for CKD, especially for early risk stratification in specific subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.